HLA-DR expression in clinical-grade bone marrow-derived multipotent mesenchymal stromal cells: a two-site study

被引：0
作者：
Marta Grau-Vorster
Anita Laitinen
Johanna Nystedt
Joaquim Vives
机构：
[1] Edifici Dr. Frederic Duran i Jordà,Servei de Teràpia Cel·lular, Banc de Sang i Teixits
[2] Universitat Autònoma de Barcelona,Transfusion Medicine Group, Vall d’Hebron Research Institute (VHIR)
[3] Advanced Cell Therapy Centre,Finnish Red Cross Blood Service
[4] Universitat Autònoma de Barcelona,Musculoskeletal Tissue Engineering Group, Vall d’Hebron Research Institute (VHIR)
[5] Universitat Autònoma de Barcelona,Departament de Medicina
来源：
Stem Cell Research & Therapy | / 10卷
关键词：
Multipotent mesenchymal stromal cell; Potency; Identity; HLA-DR; Cellular therapy; Cell culture; Quality compliance;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
相关论文
共 119 条
  • [1] Mohal JS(2012)Sources of adult mesenchymal stem cells and their applicability for musculoskeletal applications Curr Stem Cell Res Ther 7 103-109
  • [2] Tailor HD(2013)Mesenchymal stem cells: environmentally responsive therapeutics for regenerative medicine Exp Mol Med 45 e54-414
  • [3] Khan WS(2017)Characteristics, applications and prospects of mesenchymal stem cells in cell therapy Med Clin (Barc) 148 408-1413
  • [4] Murphy MB(2018)Cell, tissue and gene products with marketing authorization in 2018 worldwide Cytotherapy. 20 1401-833
  • [5] Moncivais K(2018)Mesenchymal stromal cells: clinical challenges and therapeutic opportunities Cell Stem Cell 22 824-317
  • [6] Caplan AI(2006)Minimal criteria for defining multipotent mesenchymal stromal cells. The International Society for Cellular Therapy position statement Cytotherapy. 8 315-40
  • [7] Guadix JA(2019)Levels of IL-17F and IL-33 correlate with HLA-DR activation in clinical-grade human bone marrow-derived multipotent mesenchymal stromal cell expansion cultures Cytotherapy. 21 32-1755
  • [8] Zugaza JL(2008)IFN-gamma activation of mesenchymal stem cells for treatment and prevention of graft versus host disease Eur J Immunol 38 1745-1208
  • [9] Galvez-Martin P(2016)Design and validation of a consistent and reproducible manufacture process for the production of clinical-grade bone marrow-derived multipotent mesenchymal stromal cells Cytotherapy. 18 1197-608
  • [10] Cuende N(2017)Good responses but high TRM in adult patients after MSC therapy for GvHD Bone Marrow Transplant 52 606-906
12345678910